Indigo Light May Offer a New Way to Protect Children’s Eyes From Nearsightedness
Summary: A new study from Cincinnati Children’s Hospital Medical Center and the University of Alabama at Birmingham found that exposure to specific indigo wavelengths of light prevented experimentally induced myopia in tree shrews, an animal model with visual characteristics similar to humans. The finding could eventually lead to changes in indoor lighting or new treatments for children, but researchers have not yet shown that indigo light prevents myopia in children. For families today, outdoor time and established myopia-control treatments remain the more practical options.
A new discovery about the light children see every day could eventually change how doctors think about preventing childhood nearsightedness.
Researchers at Cincinnati Children’s Hospital Medical Center and the University of Alabama at Birmingham report that exposure to indigo light wavelengths between 419 and 446 nanometers prevented experimentally induced myopia in tree shrews, an animal model whose eyes share important characteristics with human vision.
The study was published online Aug. 18 in Cell Reports Medicine. Health
The finding is important because myopia, or nearsightedness, is becoming increasingly common among children worldwide. The condition occurs when the eye grows too long, causing light to focus in front of the retina instead of directly on it. Over time, severe myopia can increase the risk of retinal detachment, glaucoma and other vision-threatening conditions.
But parents should not interpret the new research as a recommendation to expose children to blue or indigo light at home. The study was conducted in animals, and researchers still need to determine whether the approach is safe and effective in children.
Why indigo light matters
The researchers were investigating why outdoor exposure appears to protect children against myopia.
Sunlight contains a broad spectrum of wavelengths. Standard indoor LED lighting, however, does not reproduce the spectrum of sunlight exactly. The researchers focused on relatively short wavelengths of indigo light that are abundant outdoors but poorly represented in typical indoor lighting.
Their work builds on research involving OPN5, a light-sensitive protein in the retina. Earlier experiments suggested that particular short wavelengths can influence signals involved in eye growth.
The team developed a measurement called the μ-opic metric to assess how effectively different wavelengths stimulate the relevant light-sensing pathway. They found that wavelengths from 419 to 446 nanometers were particularly effective in their animal model.
In the experiments, researchers induced myopia in tree shrews using specialized lenses. The animals exposed to indigo light did not develop the expected excessive elongation of the eye.
That result is striking—but it is still an early-stage finding.
What the study does—and does not—tell parents
The most important distinction is between preventing myopia in an animal experiment and proving that a treatment prevents myopia in children.
Researchers say their next step is to investigate indigo-enriched lighting in daycare settings. That would provide an opportunity to determine whether the findings translate to real-world human environments.
Until those studies are completed, parents should not buy specialized blue-light devices or change household lighting based solely on this research.
The discovery is better understood as a potential new explanation for why the visual environment matters to developing eyes and a possible future prevention strategy.
Outdoor time remains one of the best-supported strategies
There is already substantial evidence connecting outdoor exposure with a lower risk of childhood myopia.
A 2024 systematic review and meta-analysis of seven randomized controlled trials involving more than 9,400 children and adolescents found that outdoor interventions were associated with a lower incidence of myopia and less eye elongation.
More recent evidence has continued to point in the same direction. A 2026 meta-analysis involving more than 380,000 children and adolescents found that greater outdoor activity was consistently associated with lower myopia risk. Children getting more than two hours of outdoor exposure per day had lower odds of myopia than those getting less than an hour daily.
The exact biological mechanism is still being studied, but the new indigo-light research may help explain part of the puzzle.
In other words, outdoor time may provide more than one protective signal: brighter light, a broader spectrum of wavelengths and a visual environment that is different from prolonged indoor near work.
What about screens and close-up work?
Children spend substantial portions of their days reading, studying and using digital devices at close range. Researchers continue to investigate how near work interacts with myopia risk.
For parents, the practical message is not necessarily to eliminate screens. Instead, children can benefit from regular breaks from prolonged close-up activity and opportunities to spend time outdoors.
The new research makes that environmental question even more interesting: It raises the possibility that what children are missing indoors, rather than simply what they are doing on screens, may also matter.
Treatments already available for children with myopia
For children who already have myopia or are showing rapid progression, doctors have established options for slowing eye growth.
Low-dose atropine
Low-concentration atropine eye drops are among the treatments studied for controlling myopia progression.
Research from the LAMP program has found benefits from 0.05% atropine, although treatment decisions need to be individualized by an eye-care professional.
Importantly, recent research also shows that results can vary by population and concentration. A large 2026 UK randomized trial found that 0.01% atropine slowed myopia progression compared with placebo, including a smaller increase in axial eye length.
That is one reason parents should not begin atropine treatment without guidance from an ophthalmologist or optometrist experienced in childhood myopia management.
Specialized eyeglasses
The FDA authorized Essilor Stellest eyeglass lenses in 2025 to correct myopia and slow its progression in children ages 6 to 12 when treatment begins. The lenses use tiny peripheral lenslets designed to create a defocus signal that may slow eye elongation.
The FDA reported that a two-year clinical study showed a 71% reduction in myopia progression and a 53% reduction in axial eye elongation compared with conventional single-vision lenses.
Orthokeratology
Orthokeratology, commonly called Ortho-K, uses specially designed contact lenses worn overnight to temporarily reshape the cornea.
The approach can correct daytime vision while also helping slow myopia progression in some children. Recent clinical research continues to examine Ortho-K alone and in combination with low-dose atropine.
Because overnight contact lenses require careful fitting, cleaning and follow-up, they should only be used under professional supervision.
The bigger question: What should indoor light look like?
The Cincinnati Children’s-UAB discovery raises a question that could extend well beyond eye care: Should indoor environments designed for children reproduce more of the beneficial light spectrum found outdoors?
Researchers are already moving toward human studies that could test that possibility.
If future clinical trials show that indigo-enriched lighting can safely reduce childhood myopia, schools, daycares, homes and other indoor environments could eventually become part of myopia prevention.
For now, however, the science is not there yet.
The strongest practical message for families remains simpler: encourage children to spend meaningful time outdoors, schedule breaks from prolonged close-up work, make sure they receive regular eye examinations and discuss evidence-based myopia-control options with an eye-care professional when needed.
The new indigo-light research could eventually add another tool. But for today’s parents, it is best viewed as a promising scientific clue—not yet a treatment.
Sources: University of Alabama at Birmingham: Indigo light research · FDA: Essilor Stellest authorization · 2024 systematic review of outdoor interventions · 2026 BMJ atropine trial Health